| Dr Kristen Michelle Dimitris, MD | |
|
300 Polaris Pkwy, Suite 2150, Westerville, OH 43082-7989 | |
| (614) 533-3280 | |
| (614) 533-3289 |
| Full Name | Dr Kristen Michelle Dimitris |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 16 Years |
| Location | 300 Polaris Pkwy, Westerville, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114158813 | NPI | - | NPPES |
| 0068478 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 35095745 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverside Methodist Hospital | Columbus, OH | Hospital |
| Grady Memorial Hospital | Delaware, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ohiohealth Corporation | 6305758426 | 1900 |
News Archive
Oncolytics Biotech Inc. announced today that interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases was presented at the International Symposium on Cytotoxic T-lymphocytes (CTL) and Immunostimulation being held in Pamplona, Spain.
BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.
Cephalon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease, on March 20, 2008.
A technique developed by University of California, San Diego biologists, which uses bright fluorescent dyes to reveal the activity of genes in individual cells of an organism, promises to be a boon to developmental biologists, and may provide new insight into how cancerous tumors begin and grow.
› Verified 7 days ago
| Entity Name | Ohiohealth Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545273 PECOS PAC ID: 6305758426 Enrollment ID: O20031105000532 |
News Archive
Oncolytics Biotech Inc. announced today that interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases was presented at the International Symposium on Cytotoxic T-lymphocytes (CTL) and Immunostimulation being held in Pamplona, Spain.
BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.
Cephalon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease, on March 20, 2008.
A technique developed by University of California, San Diego biologists, which uses bright fluorescent dyes to reveal the activity of genes in individual cells of an organism, promises to be a boon to developmental biologists, and may provide new insight into how cancerous tumors begin and grow.
› Verified 7 days ago
| Entity Name | Ohiohealth Urgent Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811207160 PECOS PAC ID: 3476733700 Enrollment ID: O20110203000715 |
News Archive
Oncolytics Biotech Inc. announced today that interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases was presented at the International Symposium on Cytotoxic T-lymphocytes (CTL) and Immunostimulation being held in Pamplona, Spain.
BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.
Cephalon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease, on March 20, 2008.
A technique developed by University of California, San Diego biologists, which uses bright fluorescent dyes to reveal the activity of genes in individual cells of an organism, promises to be a boon to developmental biologists, and may provide new insight into how cancerous tumors begin and grow.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kristen Michelle Dimitris, MD 5400 Frantz Rd, Suite 250, Dublin, OH 43016-4144 Ph: () - | Dr Kristen Michelle Dimitris, MD 300 Polaris Pkwy, Suite 2150, Westerville, OH 43082-7989 Ph: (614) 533-3280 |
News Archive
Oncolytics Biotech Inc. announced today that interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases was presented at the International Symposium on Cytotoxic T-lymphocytes (CTL) and Immunostimulation being held in Pamplona, Spain.
BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.
Cephalon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease, on March 20, 2008.
A technique developed by University of California, San Diego biologists, which uses bright fluorescent dyes to reveal the activity of genes in individual cells of an organism, promises to be a boon to developmental biologists, and may provide new insight into how cancerous tumors begin and grow.
› Verified 7 days ago
Dr. Asma Basem Dajani, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 85 Commerce Park Dr, Westerville, OH 43082 Phone: 148-822-2397 Fax: 614-898-5999 | |
Dr. David Justin Beckstead, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 Commerce Park Dr, Westerville, OH 43082 Phone: 614-898-3006 Fax: 614-898-3023 | |
Dr. Heber Peart Hostetter Iii, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 190 S State Street, Suite A, Westerville, OH 43081 Phone: 614-882-2349 Fax: 614-882-9005 | |
Dr. Jamie Kristen Stamps, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 444 N Cleveland Ave Ste 200, Westerville, OH 43082 Phone: 614-899-2700 Fax: 614-823-5656 | |
Nina M Tan, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 6000 Cooper Rd, Westerville, OH 43081 Phone: 614-259-5428 Fax: 614-890-5056 | |
Dr. George Franklin Calloway Ii, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 495 Cooper Rd, Westerville, OH 43081 Phone: 614-891-7878 Fax: 614-891-6888 | |
Baljit Singh Rangi, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 660 Cooper Rd Ste 800, Westerville, OH 43081 Phone: 614-818-0700 Fax: 614-818-9747 |